Informace o publikaci

Analysis of Prognostic Significance of Merkel Cell Polyomavirus in Chronic Lymphocytic Leukemia

Autoři

TRIZULJAK Jakub SROVNAL Josef PLEVOVÁ Karla BRYCHTOVÁ Yvona SEMERÁD Lukáš BAKEŠOVÁ Denisa LÉTALOVÁ Eva BENEDÍKOVÁ Andrea MAYER Jiří HAJDÚCH Marian POSPÍŠILOVÁ Šárka DOUBEK Michael

Rok publikování 2015
Druh Článek v odborném periodiku
Časopis / Zdroj Clinical Lymphoma Myeloma & Leukemia
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www http://ac.els-cdn.com/S2152265015000324/1-s2.0-S2152265015000324-main.pdf?_tid=35610b90-3b65-11e5-9c14-00000aacb35d&acdnat=1438774338_b787fb4ae3f955d7a6bbe61376e2b860
Doi http://dx.doi.org/10.1016/j.clml.2015.02.003
Obor Onkologie a hematologie
Klíčová slova Chronic lymphocytic leukemia; Merkel cell polyomavirus; Overall survival; Polymerase chain reaction; Prognostic factors
Popis Merkel cell polyomavirus (MCPyV) has been found to be associated with chronic lymphocytic leukemia (CLL). We evaluated its prognostic significance in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients. Background: Merkel cell polyomavirus (MCPyV), a ubiquitous DNA tumor virus, has been found to be associated with Merkel cell carcinoma and chronic lymphocytic leukemia (CLL). Previous studies have reported conflicting results on the frequency and potential pathogenetic role of MCPyV in CLL. The aim of this study was to evaluate MCPyV's association with CLL and its prognostic significance. Patients and Methods: Between 2006 and 2013, DNA samples obtained from CLL patients (n = 119) before treatment were tested for MCPyV using quantitative real-time polymerase chain reaction analysis and verified by gel electrophoresis. Only samples testing positive by both methods were considered valid. Results: We found that 13 (11%) of 119 CLL cases were positive for MCPyV. Between the groups of MCPyV-positive and -negative patients, there was no significant difference in the sex, age, cytogenetics, presence of p53 defect, or immunoglobulin heavy chain (IGHV) mutational status. In the subset of MCPyV-negative patients, advanced Rai stage (III to IV) was found more frequently, and therapy was initiated more often. There was no difference in overall response rate, median progression-free survival, and overall survival between both groups. We did not observe any new positivity after treatment in initially MCPyV-negative patients. Conclusion: This study provides the first analysis of the prognostic role of MCPyV in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients.
Související projekty: